STOCK TITAN

Illumina to Announce Fourth Quarter & Full Year 2020 Financial Results on Thursday, February 11, 2021

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results for the fourth quarter and full year 2020 following the close of market on Thursday, February 11, 2021.

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, February 11, 2021. Interested parties may access the live teleconference through the Investor Info section on the “company tab” at www.illumina.com. Alternatively, individuals can access the call by dialing 1 (866) 211-4597 or 1 (647) 689-6853 outside North America, both with Conference ID 3809129. To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina’s website within 24 hours after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Illumina, Inc.

NASDAQ:ILMN

ILMN Rankings

ILMN Latest News

ILMN Stock Data

18.41B
158.41M
0.24%
94.5%
3.32%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About ILMN

at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.